www.esmo.org/Conferences/European-Cancer-Congress-2015/News/Anti-tumour-Activity-Demonstrated-with-Orteronel-in-Metastatic-Castration-Resistant-Prostate-Cancer Even though Orteronel failed two previous Phase III trials in showing overall survival advantage, and the manufacturer has stopped development of the drug for prostate cancer use, this Phase III study which was initiated before the termination of those two trials has shown the drugs to be highly active in the post-docetaxel setting.
The study was itself ended early, once the other two trials were stopped.
Basically, when given after an initial round of docetaxel, it tripled the "Event-Free Survival" from 2.9 months for those on docetaxel, to 8.5 months.
Also, it produced >50% declines in PSA in 57% of people taking Orteronel.
Not sure how to read what could happen next. Since it didn't show OS, does that mean the drug is still available off-label? Would the manufacturer continue studies positioning it for off-label use? Seem silly to give up on it completely, if has been shown in Phase III trial to slow disease progression for very advanced patients.
Arthur